Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERAS 007

Next Previous
Drug Profile

ERAS 007

Alternative Names: ASN 007A; ASN-007; ERAS-007

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asana BioSciences
  • Developer Erasca
  • Class Amines; Antineoplastics; Halogenated hydrocarbons; Imidazoles; Pyrimidines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 26 Jan 2026 Erasca completes the phase Ib/II HERKULES-3 trial for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT05039177)
  • 26 Jan 2026 Erasca completes the phase Ib/II HERKULES-3 trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT05039177)
  • 08 Nov 2025 Asana BioSciences and Erasca have terminates licensing agreement for ERAS 007

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top